Aravive Inc. Stock News

Aravive shareholders have been heavily diluted and suffered substantial losses in 2022. The company has struggled for cash, but now says it has funds to last at least until a pivotal data readout in 2

Aravive (ARAV) delivered earnings and revenue surprises of 20.31% and 298.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Short squeeze stocks to watch right now. The post Best Penny Stocks To Buy?

SHort squeze penny stocks to watch right now. The post Best Penny Stocks To Buy?

HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail

Aravive (ARAV) delivered earnings and revenue surprises of 1.61% and 20.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail Mc

Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aravive (ARAV) delivered earnings and revenue surprises of 3.12% and 36.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC). 26 previously treated ccRCC patie

HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated expo

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Aravive Inc (ARAV) shares closed this week 22.9% higher than it did at the end of last week. The stock is currently up 25.1% year-to-date, down 50.4% over the past 12 months, and down 83.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Shares traded as high as $2.84 and as low as $2.21 this week.Shares closed 72.4% below its 52-week high and 27.3% above its 52-week low.Trading volume this week was 44.5% lower than the 10-day average and 10.4% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 3.9% higher than its 5-day moving average, 6.7% higher than its 20-day moving average, and 20.1% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -3097.2% The company's stock price performance over the past 12 months lags the peer average by 68.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Aravive Inc (ARAV) shares closed today at 0.5% above its 52 week low of $2.22, giving the company a market cap of $47M. The stock is currently down 59.6% year-to-date, down 61.2% over the past 12 months, and down 84.2% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 68.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 93.9% The company's stock price performance over the past 12 months lags the peer average by 93.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.